Literature DB >> 16715057

Neuroleptic drugs in dementia: benefits and harm.

Clive Ballard1, Robert Howard.   

Abstract

Neuroleptic (antipsychotic) drugs are often used to treat psychiatric symptoms frequently seen in dementia, but their use is controversial. We present a new meta-analysis to assess the efficacy of these drugs for the treatment of psychiatric symptoms in Alzheimer's disease, and discuss the more limited evidence for their potential benefits in other dementias. We recommend that these treatments be limited to the short-term treatment of psychiatric symptoms associated with serious distress or risk.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16715057     DOI： 10.1038/nrn1926

Source DB:  PubMed          Journal:  Nat Rev Neurosci        ISSN： 1471-003X            Impact factor:   34.870


  60 in total

Review 1.  Tau-targeted treatment strategies in Alzheimer's disease.

Authors:  Jürgen Götz; Arne Ittner; Lars M Ittner
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

Review 2.  Second-generation antipsychotics in dementia: beyond safety concerns. A clinical, systematic review of efficacy data from randomised controlled trials.

Authors:  Salvatore Gentile
Journal:  Psychopharmacology (Berl)       Date:  2010-07-27       Impact factor: 4.530

Review 3.  Neuropsychiatry of aggression.

Authors:  Scott D Lane; Kimberly L Kjome; F Gerard Moeller
Journal:  Neurol Clin       Date:  2011-02       Impact factor: 3.806

4.  Citalopram for agitation in Alzheimer's disease: design and methods.

Authors:  Lea T Drye; Zahinoor Ismail; Anton P Porsteinsson; Paul B Rosenberg; Daniel Weintraub; Christopher Marano; Gregory Pelton; Constantine Frangakis; Peter V Rabins; Cynthia A Munro; Curtis L Meinert; D P Devanand; Jerome Yesavage; Jacobo E Mintzer; Lon S Schneider; Bruce G Pollock; Constantine G Lyketsos
Journal:  Alzheimers Dement       Date:  2012-02-01       Impact factor: 21.566

Review 5.  Are the safety profiles of antipsychotic drugs used in dementia the same? An updated review of observational studies.

Authors:  Gianluca Trifiró; Janet Sultana; Edoardo Spina
Journal:  Drug Saf       Date:  2014-07       Impact factor: 5.606

6.  Measuring the Effectiveness of Safety Warnings on the Risk of Stroke in Older Antipsychotic Users: A Nationwide Cohort Study in Two Large Electronic Medical Records Databases in the United Kingdom and Italy.

Authors:  Janet Sultana; Andrea Fontana; Francesco Giorgianni; Silvia Tillati; Claudio Cricelli; Alessandro Pasqua; Elisabetta Patorno; Clive Ballard; Miriam Sturkenboom; Gianluca Trifirò
Journal:  Drug Saf       Date:  2019-12       Impact factor: 5.606

Review 7.  Alternatives to atypical antipsychotics for the management of dementia-related agitation.

Authors:  Michael J Passmore; David M Gardner; Yvette Polak; Kiran Rabheru
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

Review 8.  Packages of care for dementia in low- and middle-income countries.

Authors:  Martin J Prince; Daisy Acosta; Erico Castro-Costa; Jim Jackson; K S Shaji
Journal:  PLoS Med       Date:  2009-11-03       Impact factor: 11.069

9.  Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial.

Authors:  Anton P Porsteinsson; Lea T Drye; Bruce G Pollock; D P Devanand; Constantine Frangakis; Zahinoor Ismail; Christopher Marano; Curtis L Meinert; Jacobo E Mintzer; Cynthia A Munro; Gregory Pelton; Peter V Rabins; Paul B Rosenberg; Lon S Schneider; David M Shade; Daniel Weintraub; Jerome Yesavage; Constantine G Lyketsos
Journal:  JAMA       Date:  2014-02-19       Impact factor: 56.272

10.  Management of patients with Alzheimer's disease: pharmacological treatment and quality of life.

Authors:  Enrico Mossello; Elena Ballini
Journal:  Ther Adv Chronic Dis       Date:  2012-07       Impact factor: 5.091
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.